MaxCyte Bolsters Distributor Network in Asia to Meet Growing Market Demands for MaxCyte STX® and MaxCyte VLX® Transfection Systems

Gaithersburg, MD – MaxCyte®, Inc., the developer and supplier of cell engineering technology to biotechnology and pharmaceutical firms engaged in cell therapy, drug discovery and development, biomanufacturing, gene editing and immuno-oncology, today announced the appointment of distributors in Japan and Singapore to support growing market demand for its MaxCyte STX® Scalable Transfection System and MaxCyte VLX® Large Scale Transfection System in Asia.

Kiko Tech Co., Ltd., a leading biotech instrument distributor in Japan, will serve throughout Japan as the authorized distributor for the MaxCyte transfection systems for drug discovery and biomanufacturing. In addition, Bio Laboratories Pte Ltd will serve as the authorized distributor of the transfection systems in Singapore.

“Researchers in Asia continue to play an increasingly important role in the discovery and development of new biologics and small molecule drugs, and thus Asia is a focal market for MaxCyte’s instruments business,” stated

< | >